(NASDAQ: VERU) Veru's forecast annual revenue growth rate of -0.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Veru's revenue in 2025 is $10,610,392.On average, 1 Wall Street analysts forecast VERU's revenue for 2025 to be $513,043,720, with the lowest VERU revenue forecast at $513,043,720, and the highest VERU revenue forecast at $513,043,720. On average, 2 Wall Street analysts forecast VERU's revenue for 2028 to be $6,229,816,600, with the lowest VERU revenue forecast at $5,130,437,200, and the highest VERU revenue forecast at $7,329,196,000.
In 2029, VERU is forecast to generate $21,987,588,000 in revenue, with the lowest revenue forecast at $21,987,588,000 and the highest revenue forecast at $21,987,588,000.